{"preliminary_commentary":{"by_channel":{"youtube":1,"podcast":1,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"KAN-HER2 MRD","nct_id":"NCT05388149","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=kan-her2-mrd-nct05388149. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Standard T-DM1 (3.6mg/kg) IV infusion every 3 weeks administered with Neratinib (160 mg) orally once daily up to 1 year.","label":"Neratinib Arm","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-07","type":"ESTIMATED"},"conditions":["Breast Cancer","HER2-positive Breast Cancer"],"enrollment":{"count":15,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Neratinib","otherNames":["NERLYNX"],"type":"DRUG"}],"last_update":"2026-10-13","lead_sponsor":"University Health Network, Toronto","official_title":"Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Clearance of ctDNA with the addition of neratinib to trastuzumab-DM1 in patients with MRD detectable by the RaDaR assay, following standard neoadjuvant therapy, surgery, and initiation of T-DM1","timeFrame":"At week 12"}],"references":[],"start_date":{"date":"2022-12-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease","url":"https://clinicaltrials.gov/study/NCT05388149"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/kan-her2-mrd-nct05388149"}